Author

Bernard Flourie 1

1 Lyon-Sud University Hospita

EFFECTIVENESS AND SAFETY OF USTEKINUMAB 90 MG EVERY FOUR WEEKS IN CROHN'S DISEASE

Mathurin Fumery, Laurent Peyrin-Biroulet, Stéphane Nancey, Pauline Veyrard, Guillaume Bouguen, Romain Altwegg, Stéphanie Viennot, David Laharie, Jerome Filippi, Anthony Buisson, Anne BOZON, Franck Brazier, Lieven Pouillon, Bernard Flourie, Laurent Siproudhis, Lucile Boivineau, Xavier Roblin, Xavier Treton

LONG-TERM EFFICACY AND SAFETY OF USTEKINUMAB IN REFRACTORY CROHN’S DISEASE PATIENTS: A MULTICENTER RETROSPECTIVE EXPERIENCE

Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourie, Hédia Brixi, Anne Bourrier, Matthieu Allez, Bernard Duclos, Jean-Charles Grimaud, Anthony Buisson, Aurelien Amiot, Mathurin Fumery, Xavier Roblin, Laurent Peyrin-Biroulet, Jerome Filippi, Guillaume Bouguen, Vered Abitbol, Benoit Coffin, Marion Simon, David La

LONG-TERM OUTCOME AFTER INFLIXIMAB WITHDRAWAL FOR SUSTAINED REMISSION IN CROHN’S DISEASE

Catherine Reenaers, Maria Nachury, Yoram Bouhnik, David Laharie, Matthieu Allez, Jean-Louis Dupas, Aurelien Amiot, Guillaume Savoye, Romain Altwegg, Georgia Malamut, Arnaud Bourreille, Bernard Flourie, Philippe Marteau, Lucine Vuitton, Benoit Coffin, Stéphanie Viennot, Jean-Frederic Colombel, Jean Yves Mary, Edouard Louis

SERRATED POLYPS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): ENDOSCOPIC CHARACTERISTICS DIFFER FROM SERRATED POLYPS IN NO-IBD POPULATION

Driffa Moussata, Gilles Boschetti, Karine Stroeymeyt, Sarah Boyer, Stéphane Nancey, Francoise Berger, Bernard Flourie

EFFICACY AND SAFETY OF GOLIMUMAB IN CROHN’S DISEASE : A FRENCH NATIONAL RETROSPECTIVE STUDY

Chloé Martineau, Bernard Flourie, Pauline Wils, Thibaut Vaysse, Romain Altwegg, Anthony Buisson, Aurelien Amiot, Guillaume Pineton de Chambrun, Vered Abitbol, Mathurin Fumery, Xavier Hebuterne, Stéphanie Viennot, David Laharie, Laurent Beaugerie, Stéphane Nancey, Harry Sokol

ENRICHMENT OF CIRCULATING DOUBLE POSITIVE INTERLEUKIN-17 PRODUCING FOXP3+ CD4+ T CELL SUBSETS ARE ASSOCIATED WITH A HIGHER RISK OF FURTHER RELAPSE IN CROHN’S DISEASE IN REMISSION: AN OBSERVATIONAL, PROSPECTIVE MULTICENTER STUDY

Gilles Boschetti, Bernard Flourie, Xavier Roblin, Stéphane Paul, Jacques Bienvenu, Gilles Bommelaer, Anthony Buisson, Emilie Del Tedesco, Cendrine Josson, Stéphane Legastelois, Stéphane Nancey

HEAD-TO-HEAD COMPARISON OF 5 FECAL MARKERS TO PREDICT RESPONSE TO INDUCTION AND MAINTENANCE THERAPY WITH INFLIXIMAB IN ULCERATIVE COLITIS PATIENTS; A PROSPECTIVE STUDY.

Anne Frin, Stéphane Nancey, Jerome Filippi, Gilles Boschetti, Bernard Flourie, Jocelyne Drai, Patricia Ferrari, Xavier Hebuterne

THE MEASURE OF TROUGH LEVELS OF INFLIXIMAB IS LINKED TO THERAPEUTIC RESPONSE IN IBD PATIENTS.

Xavier Roblin, Anne-Emmanuelle Berger, Gilles Boschetti, Bernard Flourie, Stéphane Nancey, Stéphane Paul

USTEKINUMAB EFFICACY AND SAFETY IN CROHN’S DISEASE PATIENTS REFRACTORY TO CONVENTIONAL AND ANTI-TNF THERAPY: A MULTICENTER RETROSPECTIVE EXPERIENCE

Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourie, Hedia Brixi- Benmansour, Jacques Cosnes, Matthieu Allez, Bernard Duclos, Jean-Charles Grimaud, Anthony Buisson, Aurelien Amiot, Mathurin Fumery, Xavier Roblin, Laurent Peyrin-Biroulet, Jerome Filippi, Guillaume Bouguen, Vered Abitbol, Benoit Coffin, Marion Sim

ACCURACY OF FECAL CALPROTECTIN IN THE ASSESSMENT OF POST-OPERATIVE ENDOSCOPIC RECURRENCE IN PATIENTS WITH CROHN’S DISEASE

Gilles Boschetti, Gildas Phelip, Driffa Moussata, Anne-Laure Charlois, Bernard Flourie, Stéphane Nancey, Anne-Laure Charlois

Item 1 - 10 / 14
1
2